טוען...
Overcoming acquired resistance of EGFR-mutant NSCLC cells to osimertinib by combining osimertinib with the HDAC inhibitor, panobinostat (LBH589)
BACKGROUND: The major clinical obstacle that limits the long-term benefits of treatment with osimertinib (AZD9291 or TAGRISSO™) in patients with EGFR-mutant non-small cell lung cancer (NSCLC) is the development of acquired resistance. Therefore, effective strategies that can overcome osimertinib acq...
שמור ב:
| הוצא לאור ב: | Cancer |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7241261/ https://ncbi.nlm.nih.gov/pubmed/31999837 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32744 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|